S M Keller

Summary

Affiliation: Montefiore Medical Center
Country: USA

Publications

  1. pmc Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients
    Weiguo Han
    Wadsworth Center, Human Toxicology and Molecular Epidemiology, Albany, NY, USA
    Respir Res 10:86. 2009
  2. doi request reprint Diagnosis of palmar hyperhidrosis via questionnaire without physical examination
    Steven M Keller
    Department of Cardiothoracic Surgery, Montefiore Medical Center, 3400 Bainbridge Ave, Suite 5A, Bronx, NY 10467, USA
    Clin Auton Res 19:175-81. 2009
  3. ncbi request reprint Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease
    Steven M Keller
    Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY 10467, USA
    J Thorac Cardiovasc Surg 128:130-7. 2004
  4. ncbi request reprint Adjuvant therapy for locally advanced non-small cell lung cancer
    Steven M Keller
    Department of Cardiothoracic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, 3400 Bainbridge Ave, Suite 5B, Bronx, NY 10467, USA
    Lung Cancer 42:S29-34. 2003
  5. ncbi request reprint Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer
    Steven M Keller
    Department of Cardiothoracic Surgery, The Montefiore Medical Center, 3400 Bainbridge Ave, Suite 5B, Bronx, NY 10467, USA
    Lung Cancer 42:79-86. 2003
  6. ncbi request reprint The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer
    S M Keller
    Department of Cardiothoracic Surgery, Montefiore Medical Center, 3400 Bainbridge Ave, Suite 5B Bronx, New York, NY 10467, USA
    Lung Cancer 37:303-9. 2002
  7. ncbi request reprint Complete mediastinal lymph node dissection---does it make a difference?
    Steven M Keller
    Department of Surgery, Beth Israel Medical Center, First Ave and 16th St, New York, NY 10003, USA
    Lung Cancer 36:7-8. 2002
  8. ncbi request reprint A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group
    S M Keller
    Department of Surgery, Beth Israel Medical Center, New York, NY 10003, USA
    N Engl J Med 343:1217-22. 2000
  9. ncbi request reprint Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Eastern Cooperative Oncology Group
    S M Keller
    Department of Surgery, The Beth Israel Medical Center, New York, New York 10003, USA
    Ann Thorac Surg 70:358-65; discussion 365-6. 2000
  10. ncbi request reprint Neoadjuvant and adjuvant therapy of non-small cell lung cancer
    Lakshmi Rajdev
    Albert Einstein College of Medicine, Bronx, NY, USA
    Surg Oncol 11:243-53. 2002

Collaborators

Detail Information

Publications19

  1. pmc Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients
    Weiguo Han
    Wadsworth Center, Human Toxicology and Molecular Epidemiology, Albany, NY, USA
    Respir Res 10:86. 2009
    ..There is a need for new, noninvasive risk assessment tools for use in lung cancer population screening and prevention programs...
  2. doi request reprint Diagnosis of palmar hyperhidrosis via questionnaire without physical examination
    Steven M Keller
    Department of Cardiothoracic Surgery, Montefiore Medical Center, 3400 Bainbridge Ave, Suite 5A, Bronx, NY 10467, USA
    Clin Auton Res 19:175-81. 2009
    ..The reliable diagnosis of PH via questionnaire would enable molecular epidemiological studies without the need for physical examination or direct sweat measurement...
  3. ncbi request reprint Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease
    Steven M Keller
    Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY 10467, USA
    J Thorac Cardiovasc Surg 128:130-7. 2004
    ....
  4. ncbi request reprint Adjuvant therapy for locally advanced non-small cell lung cancer
    Steven M Keller
    Department of Cardiothoracic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, 3400 Bainbridge Ave, Suite 5B, Bronx, NY 10467, USA
    Lung Cancer 42:S29-34. 2003
  5. ncbi request reprint Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer
    Steven M Keller
    Department of Cardiothoracic Surgery, The Montefiore Medical Center, 3400 Bainbridge Ave, Suite 5B, Bronx, NY 10467, USA
    Lung Cancer 42:79-86. 2003
    ..The majority of SPTs occur outside the aerodigestive tract. Following development of a non-skin SPT, the survival difference between patients who had received adjuvant CRT and those treated with adjuvant RT alone was not significant...
  6. ncbi request reprint The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer
    S M Keller
    Department of Cardiothoracic Surgery, Montefiore Medical Center, 3400 Bainbridge Ave, Suite 5B Bronx, New York, NY 10467, USA
    Lung Cancer 37:303-9. 2002
    ..Gender does not influence survival following adjuvant RT or CRT administered to patients with completely resected stages II and IIIa NSCLC. However, women with non-squamous histology have increased survival when compared to men...
  7. ncbi request reprint Complete mediastinal lymph node dissection---does it make a difference?
    Steven M Keller
    Department of Surgery, Beth Israel Medical Center, First Ave and 16th St, New York, NY 10003, USA
    Lung Cancer 36:7-8. 2002
  8. ncbi request reprint A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group
    S M Keller
    Department of Surgery, Beth Israel Medical Center, New York, NY 10003, USA
    N Engl J Med 343:1217-22. 2000
    ....
  9. ncbi request reprint Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Eastern Cooperative Oncology Group
    S M Keller
    Department of Surgery, The Beth Israel Medical Center, New York, New York 10003, USA
    Ann Thorac Surg 70:358-65; discussion 365-6. 2000
    ....
  10. ncbi request reprint Neoadjuvant and adjuvant therapy of non-small cell lung cancer
    Lakshmi Rajdev
    Albert Einstein College of Medicine, Bronx, NY, USA
    Surg Oncol 11:243-53. 2002
    ..Phase II and III trials with traditional radiotherapy schedules and cytotoxic drugs have produced conflicting results. Novel approaches utilizing long-term administration of less toxic drugs and targeted biologic therapies are promising...
  11. ncbi request reprint Adjuvant therapy of resected non-small-cell lung cancer
    S M Keller
    Department of Surgery, Beth Israel Medical Center, New York, New York 10804, USA
    Curr Opin Oncol 12:149-55. 2000
    ..However, recent phase II and III trials and a meta-analysis have produced conflicting results. Postoperative adjuvant therapy remains a subject of active investigation...
  12. doi request reprint Intraoperative staging and surgical management of stage IIIA/N2 non-small cell lung cancer
    Igor Brichkov
    Department of Cardiothoracic Surgery, Division of Thoracic Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, 3400 Bainbridge Avenue 5th floor, Bronx, NY 10467, USA
    Thorac Surg Clin 18:381-91. 2008
    ..Cisplatin-based adjuvant chemotherapy has moderate but proven survival benefit after resection of N2 disease. The role of PORT remains uncertain...
  13. ncbi request reprint Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression
    Marie Emmanuelle Legrier
    Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Cancer Res 67:11300-8. 2007
    ..These data (a) provide evidence that both pathways converge on factors that regulate translation initiation and (b) support therapeutic strategies in lung cancer that simultaneously suppress the RAS and AKT signaling network...
  14. ncbi request reprint (18)F-fluorodeoxyglucose positron emission tomography: false-positive lung scan
    A H Khandani
    Departments of Nuclear Medicine and Cardiothoracic Surgery, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY 10461, USA
    Semin Nucl Med 32:212-3. 2002
  15. ncbi request reprint Sensitivity of FDG PET, GLUT1 expression and proliferative index in bronchioloalveolar lung cancer
    Amir H Khandani
    Department of Nuclear Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, New York, USA
    Nucl Med Commun 28:173-7. 2007
    ..To estimate the sensitivity of [F] fluorodeoxyglucose (FDG) positron emission tomography (PET) and to assess the expression of glucose transporter 1 (GLUT1) and proliferative index (PI) in bronchioloalveolar lung cancer (BAC)...
  16. ncbi request reprint Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group
    Heather A Wakelee
    Stanford Clinical Cancer Center, 875 Blake Wilbur Drive, Room 2231, Stanford, CA 94305 5826, USA
    Lung Cancer 48:389-97. 2005
    ..The risk of DID following resection of stages II and IIIA NSCLC is not increased in patients who received PORT or CPORT...
  17. ncbi request reprint The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer
    Noriyoshi Sawabata
    Division of Surgery, Toneyama National Hospital, 5 1 1 Toneyama, Toyonaka, Osaka 560 8552, Japan
    Lung Cancer 42:69-77. 2003
    ....
  18. pmc Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590
    Daniel B Costa
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA, United States
    Lung Cancer 56:97-103. 2007
    ..This is the first comprehensive study of this transcription factor in patients with NSCLC...
  19. ncbi request reprint EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer
    Sarita Dubey
    University of California, San Francisco, San Francisco, California 94115, USA
    J Thorac Oncol 1:406-12. 2006
    ..The authors hypothesized that a shorter length of tumor SSR would be associated with poorer survival in patients with non-small cell lung cancer (NSCLC)...